{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"1","upperLimit":"3","value":"2.0"},{"groupId":"OG001","lowerLimit":"2","upperLimit":"3","value":"2.0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"11"},{"groupId":"OG001","value":"4"}],"units":"Participants"}],"description":"Time to first onset of Grade ≥2 CRS in participants receiving prophylactic anakinra relative to onset of Grade ≥ 2 CRS in participants treated at the RP2D(s) in the Phase 1 dose escalation portion of the trial. Time to onset is calculated from the latest JCARH125 infusion prior to the first onset of Grade \\>= 2 CRS. CRS grade is defined by the most severe symptom (excluding fever). Grade 2=moderate; Grade 3=severe; Grade 4=life-threatening","dispersionType":"Full Range","groups":[{"description":"JCARH125 IV at dose level 600 x 10\\^6 consisting of CD3+CAR+T cells","id":"OG000","title":"Phase 1 600 x 10^6 Cells"},{"description":"2 doses of 100 mg anakinra administered subcutaneously (SC) for 5 consecutive days + JCARH125 IV at dose level 600 x 10\\^6 consisting of CD3+CAR+T cells","id":"OG001","title":"Phase 1 Anakinra 600 x 10^6 Cells"}],"paramType":"MEDIAN","populationDescription":"All participants with grade ≥2 CRS who received at least one infusion of JCARH125 (and at least one dose of anakinra as prophylactic intervention for phase 1 Anakinra) at dose level 600 x 10\\^6 in phase 1 and in phase 1 Anakinra","reportingStatus":"POSTED","timeFrame":"From JCARH125 infusion to the first onset of Grade ≥2 CRS (Up to approximately 61 months)","title":"Time to Onset of Grade ≥2 Cytokine Release Syndrome (CRS) in Phase 1 and Phase 1 Anakinra","type":"PRIMARY","unitOfMeasure":"Days"}